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Butyrate, produced in the colon by fermentation of dietary fibre, induces apoptosis in colon adenoma and cancer cell lines, which may
contribute to protection against colorectal cancer. However, butyrate is present in the colon along with other dietary factors,
including unconjugated bile acids, which are tumour promoters. We have shown previously that the proapoptotic effects of butyrate
on AA/C1 human adenoma cells were reduced in the presence of bile acids. To determine the cellular basis of this interaction, we
examined the effects of butyrate and the secondary bile acid ursodeoxycholic acid (UDCA) on signalling pathways known to regulate
apoptosis using AA/C1 cells. Butyrate activated PKC-d and p38 MAP (mitogen-activated protein) kinase, whereas UDCA activated
PKC-a and p42/44 MAP kinase. Butyrate treatment also resulted in the caspase-3-mediated proteolysis of PKC-d. Butyrate-induced
apoptosis was reduced by inhibitors of PKC-d (Rottlerin), p38 MAP kinase (SB202190) and caspase 3 (DEVD-fmk), whereas the
proliferative/survival effects of UDCA were blocked by inhibitors of PKC-a (Go ¨6976) and MEK 1 (PD98059). The effects of butyrate
and bile acids are therefore mediated by the differential activation of signalling pathways that are known to regulate apoptosis.
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A diet high in dietary fibre and low in saturated fats is associated
with a reduced incidence of colorectal cancer (Sandler et al, 1993).
The benefits of a high intake of dietary fibre have been attributed
to their fermentation in the gut to short-chain fatty acids,
including butyrate. Butyrate has been shown to increase apoptosis
in both colon adenoma and cancer cell lines in a p53-independent
way (Hague et al, 1993), an effect that is likely to contribute
significantly to its protective effects. In contrast, a diet high in
saturated fats is associated with an increased level of faecal
secondary bile acids (Radley et al, 1993) and an increased risk of
colorectal cancer (Reddy and Wynder, 1977). Secondary bile acids,
deoxycholic acid (DCA), ursodeoxycholic acid (UDCA) and
lithocholic acid, are produced by the actions of intestinal bacteria
on primary bile acids. Unconjugated bile acids have been shown to
be tumour promoting in rodent colonic epithelium (Narisawa et al,
1974; Mahmoud et al, 1999).
The majority of studies in the literature concerning the effects of
butyrate and bile acids on colonic epithelial cell proliferation and
apoptosis have considered these dietary factors individually. In
vivo both are present in the colon and may influence each other’s
actions directly or indirectly. For example, butyrate is known to
modify colonic pH and inhibit the colonic bacteria responsible for
the production of bile acids (MacDonald et al, 1978). We have
shown previously that human adenoma cells, AA/C1, treated with
physiological levels of bile acids showed increased proliferation
(McMillan et al, 2000). Butyrate induced apoptosis in AA/C1 cells
(Hague et al, 1993; McMillan et al, 2000) and addition of bile acids
to these cells reduced the level of apoptosis, although this effect
could be overcome by increasing the level of butyrate (McMillan
et al, 2000). Therefore, these two dietary factors interact at the
cellular level and the protective effect of butyrate may relate
both to its apoptosis-inducing effect per se and its ability to
modify the antiapoptotic, proliferative effects of secondary bile
acids.
The molecular basis for the proapoptotic effects of butyrate have
not been fully worked out, although it does not involve induction
of Fas expression or modulation of bcl-2 family protein expression
(Bonnotte et al, 1998; Giardina et al, 1999). However, a study by
Medina et al (1997) has shown that butyrate induced activation of
caspase 3 in colorectal cancer cells. Caspase 3 is a member of a
cysteine protease family that are involved specifically with the
initiation and execution of the apoptotic programme (reviewed in
Kumar, 1995). Caspase 3 is a downstream effector caspase that is
activated by upstream caspases, predominantly caspases 8 and 9.
Caspase 3 can be activated by several routes, these include ligation
of cell surface receptors, such as Fas (Enari et al, 1996), which are
associated with caspase 8; or by factors released from mitochon-
dria, that is, cytochrome c (Liu et al, 1996), in response to cellular
stress, which in turn activate caspase 9 (Liu et al, 1996). Caspase 3
can also be activated by factors, including cellular stress, which
leads to activation of the p38 MAP (mitogen-activated protein)
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ykinase pathway, independent of the mitochondria (Shimizu et al,
1999).
The tumour-promoting effects of bile acids have been ascribed
predominantly to their potent activation of protein kinase C (PKC)
(Huang et al,1 9 9 2 ) .P K Ci saf a m i l yo f1 1i s o e n z y m e st h a ta r e
differentially regulated and play specific roles in the control of cell
proliferation, differentiation and apoptosis (Clemens and Trayner,
1992; Deacon et al, 1997). With respect to apoptosis, PKC-a and -bll
appear to be antiapoptotic in most cells. PKC-a is inactivated by
proapoptotic factors including ceramide (Lee et al, 1996) and is
known to phosphorylate bcl-2, potentiating its antiapoptotic function
in mitochondria (Ruvolo et al, 1998). PKC-bll is a mitotic lamin
kinase (Goss et al, 1994) involved in the regulation of proliferation. In
contrast, PKC-d has a proapoptotic function and can be activated
proteolytically by caspase 3 (Ghayur et al, 1996). Furthermore,
transfection of cells with the caspase-3-generated fragment of PKC-d
is sufficient to induce apoptosis, while the same fragment mutated to
inactivate the kinase domain is ineffective (Ghayur et al, 1996). In this
study, we have considered the interaction between bile acids and
butyrate by investigating the signalling pathways activated to effect
their pro- and antiapoptotic actions.
MATERIALS AND METHODS
Cell culture
The colorectal adenoma cell line AA/C1 was provided by Professor
C Paraskeva (Manning et al, 1991) and was cultured as described
previously (Williams et al, 1990). Prior to treatment with bile acids
or butyrate, cells were trypsinised and seeded at 10
6cells per flask,
in triplicate, in DMEM (Gibco-BRL, Paisley, Scotland), containing
20% FCS (Sera Laboratories International, Crawley, UK), 2mM
glutamine, 0.2Uml
 1 insulin, 1mgml
 1 hydrocortisone sodium
succinate (Sigma, Poole, UK), 100Uml
 1 penicillin and
100mgml
 1 streptomycin. After 3 days, the medium was replaced
with a medium containing 6mM sodium butyrate or 10mM UDCA
(Sigma, UK). UDCA was added to the medium from a 10mM stock
in DMSO and solvent controls were used throughout.
Assessment of PKC isoenzyme activation
PKC resides in the cytosol in its inactive state and translocates to the
membrane fraction upon activation. Following treatment with bile
acid and butyrate, cells were harvested by scraping, lysed and cytosol
(soluble) and membrane (particulate) fractions were isolated by
centrifugation as previously described (Griffiths et al,1 9 9 6 ) .B r i e f l y
cell lysates were spun at 100000 g for 45min at 41C, the
supernatant (soluble fraction) was removed and the pellet (particulate
fraction) was extracted in lysis buffer (50mM Tris-HCl, pH 7.4, 5mM
MgCl2,1 m M EGTA, 1mM EDTA, 100mgml
 1 leupeptin, 10mgml
 1
pepstatin and 1mM PMSF) containing 0.5% Triton X-100. Both
fractions were then taken up in SDS sample buffer and proteins were
separated on 10% SDS–PAGE gels. Protein content of each sample
was determined prior to electrophoresis and 20mg was loaded per
lane. Proteins were then transferred to PVDF membrane (Immobilon
P, Millipore, UK) and the PKC isoenzymes were detected by
immunoblotting. Rabbit polyclonal antibodies to PKC-a,- b (l and
ll), -d (Santa Cruz Biotechnology, US), -e,- Z and -z (Transduction
Laboratories, US) and HRP-conjugated anti-rabbit IgG antibodies
(Amersham International plc, UK) were used and blots were
developed using enhanced chemiluminescence (ECL, Amersham,
UK). Equivalent loading was confirmed using an anti-b actin
antibody (Sigma, UK).
Measurement of p38 and p42/44 MAP kinase activation
Activation of p38 and p42/44 MAP kinases was determined by
immunoblotting of whole cell extracts using antibodies that detect
the phosphorylated, active form of these kinases (Upstate
Biotechnology, US). Blots were developed using ECL. Equivalent
loading was confirmed using antibodies that detect total p38 and
p42/44 MAP kinase.
Measurement of apoptosis
In studies to determine the effect of inhibitors of caspase 3, PKC
isoenzymes and MAP kinases on the regulation of apoptosis by
bile acids and butyrate, inhibitors were included in the culture
medium with these agents and apoptosis was measured after 72h.
A volume of 0.1mM Go ¨6976 (Calbiochem, UK) and 20mM Rottlerin
(Calbiochem, UK) were used to inhibit PKC-a and b and PKC-d,
respectively, and 10mM PD98059 and 1mM SB202190 (Calbiochem,
UK) were used as inhibitors of MEK 1, which lies upstream of p42/
44 MAP kinase and p38 MAP kinase, respectively. To confirm the
involvement of caspase 3 in butyrate-induced apoptosis, the
caspase 3 inhibitor Ac-DEVD-fmk (Calbiochem, UK) was used at
10 and 50mM. The concentrations of inhibitors used were based on
their IC50 values and our previous experience with these agents
(Pongracz et al, 1999; Cross et al, 2000). Apoptosis was assessed by
measuring annexin V binding and exclusion of propidium iodide,
in both attached and floating cells, using a commercial kit
(Boehringer-Mannheim, Germany) and FACS analysis.
Statistics
Data are presented as mean7standard deviation (s.d.) and means
were compared by Student’s t-test. A value of Po0.05 was taken to
indicate a significant difference between the mean values.
RESULTS
Effect of sodium butyrate and UDCA on apoptosis
of AA/C1 cells
The basal level of apoptotic cells detected in AA/C1 cultures was
12.7570.8%. As shown previously (Hague et al, 1993; McMillan
et al, 2000), sodium butyrate (6mM) induced a significant increase
in apoptosis in AA/C1 adenoma cells (Po0.005; Figure 1). In
contrast, 10mM UDCA had no effect on spontaneous apoptosis of
AA/C1, but did inhibit butyrate-induced apoptosis (Figure 1).
Effect of sodium butyrate and UDCA on PKC isoenzyme
activation
PKC-a, bl, bll and d were detected in AA/C1 cells and were the
predominant isoenzymes expressed in these cells (Figure 2A).
PKC-e,- Z and -z were also detected, but were expressed at a low
level and were not affected by either bile acid or butyrate
treatments (data not shown). Treatment of AA/C1 cells
(Figure 2A) with 6mM sodium butyrate induced a modest
translocation of full-length 78kDa PKC-d from the soluble to the
particulate fraction, 2h after addition of butyrate. Densitometric
analysis of blots from three separate experiments showed that the
percentage of total PKC-d present in the particulate fraction
increased from 52.474% in untreated cells to 88.379% in
butyrate-treated cells. Translocation of PKC-a,- bl and -bll was
not detected in response to butyrate treatment (Figure 2A), even
up to 24h after addition of butyrate (data not shown). Further
studies revealed that a 40kDa protein was detected by the anti-
PKC-d antibody in butyrate-treated cells. This fragment was not
detected until 18–24h of butyrate treatment and after the
translocation of full-length PKC-d (Figure 2B). PKC-d can be
proteolytically activated by caspase 3, leading to the generation of
a constitutively active 40kDa fragment (Ghayur et al, 1996). The
appearance of the 40kDa PKC-d fragment was inhibited by
inclusion of the caspase 3 inhibitor Ac-DEVD-fmk in
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ybutyrate-treated cultures (Figure 2B), suggesting that this repre-
sented the caspase activated form of PKC-d.
Treatment of AA/C1 cells with 10mM UDCA induced transloca-
tion of PKC-a to the particulate fraction after 24h, with no
consistent change detected for the other PKC isoenzymes
(Figure 2C). Densitometric analysis of three blots showed that
the fraction of PKC-a associated with the particulate fraction
increased from 27.474% in untreated to 59.877% in UDCA-
treated cells. Thus, PKC isoenzymes were activated differentially
by butyrate and UDCA.
Effect of butyrate and UDCA on p38 and p42/44 MAP
kinase activation
Butyrate (6mM) induced activation of p38 MAP kinase in AA/C1
cells, indicated by an increase in the level of phosphorylated p38
MAP kinase, but did not induce activation of p42/44 MAP kinase
(Figure 3). In contrast, active p42/44 MAP kinase was increased in
cultures of AA/C1 treated with UDCA (Figure 3) and 10mM UDCA
did not increase levels of activated p38 MAP kinase (Figure 3).
Therefore, butyrate activated p38 MAP kinase, which has been
shown to be involved in pathways leading to apoptosis and UDCA
activated the p42/44 MAP kinase pathway, which has been
implicated in cell proliferation and survival.
Effect of PKC, MAP kinase and caspase 3 inhibitors
on the actions of butyrate and UDCA
To determine whether the signals through the PKC and MAP
kinase pathways were required for the effects of butyrate and
UDCA, inhibitors of these pathways were used. The PKC-d
inhibitor Rottlerin and the p38 MAP kinase inhibitor SB202190
blocked apoptosis induced by butyrate (Figure 4A). As PKC-d was
also activated via caspase 3, the effects of the inhibitor Ac-DEVD-
fmk were determined. Ac-DEVD-fmk also reduced apoptosis in
butyrate-treated cultures (Figure 4A). The MEK 1 inhibitor
PD98059 inhibits the activation of p42/44 MAP kinase indirectly
and did not inhibit the proapoptotic actions of butyrate
(Figure 4A). PD98059 blocked the effect of UDCA, inhibiting the
increase in cell number seen with this bile acid (Figure 4B). The
proliferative effect of UDCA was confirmed by measuring thy-
midine incorporation, which showed that incorporation of tritiated
thymidine increased from 48.970.9 to 60.272.1 10
3d.p.m. per
10
5cells after 96h treatment. The proliferative effects of UDCA
were also reduced by Go ¨6976 (Figure 4B), an inhibitor of PKC-a
and -b that does not affect PKC-d (Gschwendt et al, 1996),
confirming that both PKC and p42/44 MAP kinase are involved in
mediating the effects of UDCA. The p38 MAP kinase inhibitor































Figure 1 Effect of butyrate and UDCA on apoptosis in AA/C1 cells.
Levels of apoptotic cells were determined in cultures of AA/C1 colon
adenoma cells treated for 72h with 6mM sodium butyrate alone, 10mM
sodium UDCA alone or butyrate and UDCA in combination. Apoptosis
was assessed by binding of annexin V and exclusion of propidium iodide.






















Figure 2 Effect of butyrate and UDCA treatment on PKC isoenzyme
activation. PKC isoenzymes (a, bl, bll and d) were measured by Western
blotting in soluble and particulate fractions of (A) AA/C1 cells treated with
or without 6mM sodium butyrate for 2h or (C)1 0mM UDCA for 24h. (B)
The 40kDa fragment of PKC-d was detected in whole cell lysates of AA/
C1 cells treated for 18h with 6mM sodium butyrate in the absence or
presence of the caspase 3 inhibitor Ac-DEVD-fmk. b-Actin was also
measured as a loading control. The estimated molecular weights on the
immunoreactive bands in (A) are shown on the right side of the figure. The
blots shown are representative of three separate experiments performed.
Butyrate, bile acids and apoptosis
L McMillan et al
750





























y(Figure 4B). The inhibitor studies thus confirmed that modulation
of PKC and MAP kinase signalling pathways by butyrate and
UDCA was involved in mediating their effects on colorectal
adenoma cell apoptosis and proliferation.
DISCUSSION
In all tissues, including the colon, cell number and phenotype are
maintained by a correct balance between cell proliferation,
differentiation and apoptosis. Disruption of this balance underlies
the development of cancer (Williams, 1991). In the colonic crypt,
stem cells are located at the base and as they differentiate they
progress up the crypt, eventually dying by apoptosis and are
sloughed off into the colonic lumen (Potten and Grant, 1998). The
high incidence of colorectal cancer in Western society has been
attributed to a diet high in saturated fat and low in dietary fibre
(Sandler et al, 1993). A high intake of saturated fat results in
increased production of bile acids and raised levels of secondary
bile acids, produced in the colon (Hill, 1986), have been measured
in patients with adenomatous polyps and colorectal cancer (Radley
et al, 1993). While bile acids are not mutagenic, they have been
shown to act as tumour promoters in animal studies (Narisawa
et al, 1974; Mahmoud et al, 1999) and PKC has been identified as
their molecular target (Pongracz et al, 1995). We confirm here that
the secondary bile acid UDCA was able to activate PKC in whole
cells (Huang et al, 1992) and show that this action was restricted to
the classical PKC isoenzyme PKC-a. Although UDCA was the focus
of this study, we have also shown that other bile acids can inhibit
butyrate-induced apoptosis, including CDCA (McMillan et al,
2000), and this bile acid also activates PKC-a (data not shown).
Interestingly, the literature suggests that PKC-a has a predomi-
nantly antiapoptotic role (Deacon et al, 1997). For example, PKC-a
is inhibited during ceramide-induced apoptosis (Lee et al, 1996)
and expression of a dominant-negative PKC-a induced apoptosis
in CHO cells (Whelan and Parker, 1998). Thus, those bile acids
known to promote cell proliferation and inhibit butyrate-induced
apoptosis, that is, UDCA, CDCA and DCA (Mahmoud et al, 1999;
McMillan et al, 2000), are likely to be mediated by the activation of
PKC-a. This proposal is supported by the ability of the PKC
inhibitor Go ¨6976 to block the proliferative effects of UDCA on AA/
C1 cells.
Our studies also revealed that a kinase lying downstream of
PKC-a, namely p42/44 MAP kinase, was also activated following
UDCA treatment. This kinase is the original member of the
mitogen-activated protein kinase family (MAP kinases) that are
activated by a variety of mitogens, including growth factors and
the PKC activator TPA (Kyriakis et al, 1994). PKC-a is known to
phosphorylate and activate Raf-1, a serine threonine kinase that
activates the kinase upstream of p42/44 MAP kinase, MEK1 (Kolch
et al, 1993). Inhibition of MEK1 was able to block the effects of
UDCA, confirming that the PKC-a and p42/44 MAP kinase play a
role in mediating the effects of bile acids on AA/C1 cells.
In contrast to the activation of survival/proliferative pathways
by UDCA, butyrate was found to activate pathways known to
mediate cell death by apoptosis, namely PKC-d and p38 MAP
kinase, consistent with the induction of apoptosis by this agent
(Hague et al, 1993; McMillan et al, 2000). Butyrate has also been
shown to activate p38 MAP kinase in Caco-2 cells (Ding et al,
2001). Loss of PKC-d protein expression has been reported in
human adenocarcinoma tissue (Craven and deRubertis, 1994) and
this may underlie the reduced responsiveness of cancer tissue to
the apoptosis-inducing effects of butyrate (Bonnotte et al, 1998).
Butyrate has been shown previously to activate NF-kB in a PKC-
dependent manner, although the PKC isoenzyme involved was not
determined (Giardina et al, 1999). A signalling pathway involving
both p38 MAP kinase and NF-kB and leading to activation of
caspase 3 has been described (Ichijo et al, 1999; Shimizu et al,
1999). Our data suggest therefore that activation of full-length
PKC-d, which occurred before caspase 3 activation of PKC, may
initiate the signals leading to p38 MAP kinase and NF-kB
activation. The latter will then result in caspase 3 activation and
further activation of PKC-d by caspase-3-mediated proteolysis.










Figure 3 Effect of butyrate and UDCA on p38 and p42/44 MAP kinase
activity. AA/C1 cells treated with 6mM butyrate or 10mM UDCA for 24h.
Cells were examined for the presence of activated, phosphorylated p38
MAP kinase (pP38) and p42/44 MAP kinase (pP42/44) by Western
blotting. PD98059 was also included with UDCA treatments (lane 5) to
inhibit activation of p42/44 MAP kinase by MEK1, and SB202190 was
included with butyrate treatments (lane 3) to inhibit p38 MAP kinase. Equal
loading of gels was confirmed using an antibody to total P38 and P42/44



















































































Figure 4 Effect of PKC, MAP kinase and caspase 3 inhibitors on the
effects of UDCA and butyrate. (A) AA/C1 cells were incubated with 6mM
butyrate alone and in the presence of 10mM PD98059, 1mM SB202190,
20mM Rottlerin or 20mM Ac-DEVD-fmk. Apoptosis was measured after
72h by annexin V binding and exclusion of propidium iodide. Values for
butyrate treatment were compared with butyrate combined with the
inhibitors used. (B) AA/C1 cells were incubated with 10mM UDCA in the
absence or presence of 10mM PD98059, 1mM SB202190 or 0.1mM
Go6976. Attached cell number was measured after 96h and expressed
as a percentage of the value for untreated cells. Data are mean 7s.d. of
three separate experiments and *denotes Po0.05 and **denotes Po0.01.
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ycaspase 3 activation via the mitochondrial route. The latter
involves generation of reactive oxygen species and release of
cytochrome c from the mitochondria. Thus, caspase 3 activation by
butyrate is achieved by two pathways and will ensure that cleavage
and activation of the proapoptotic PKC-d is achieved.
The targets of PKC-d that effect its involvement in apoptosis
have not been fully described, but appear to include predomi-
nantly nuclear proteins. The caspase-3-activated form of PKC-d
has been shown to inhibit DNA-PK, a nuclear protein involved in
DNA repair (Bharti et al, 1998) and to phosphorylate nuclear lamin
B prior to disassembly of the nuclear lamina (Cross et al, 2000).
Although translocation of PKC-d was shown here, the particular
membrane involved was not identified. However, we have shown
previously that PKC-d translocated to the nuclear membrane
during apoptosis in T cells, HL60 cells and neutrophils (Pongracz
et al, 1999; Scheel-Toellner et al, 1999; Cross et al, 2000).
In summary, we have shown that the opposing effects of bile
acid and butyrate, used at concentrations within the physiological
range, on colon adenoma cell apoptosis are mediated via
differential activation of signalling pathways that regulate apop-
tosis. The ultimate level of apoptosis in the colon may therefore be
dictated by the balance of signals through the pro- and
antiapoptotic PKC isoenzymes and MAP kinases. Such a proposal
is supported by the data of Ding et al (2001), which showed that
butyrate-induced apoptosis of Caco-2 cells was potentiated by the
MEK inhibitor PD98059 and involved activation of p38 MAP
kinase as reported here. Any beneficial effects of butyrate with
regard to colon cancer will only be realised if levels of this agent
are high enough in the colon to overcome the tumour-promoting
signals induced by unconjugated bile acids.
Future studies will determine whether the signalling pathways
activated by bile acids are able to inhibit directly the activation of
proapoptotic signalling pathways, PKC-d and p38 MAP kinase,
activated by butyrate, or whether they act downstream of these
signals, for example by inducing the phosphorylation and
activation of bcl-2 (Ruvolo et al, 1998).
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